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Transparency Is the Key to the Relationship 
between Biomedical Journals and Medical 
Writers
The role of professional medical writers in the biomedical literature has been a topic of heated debate. As publication in peer-
reviewed journals is the standard of currency for 
researchers, the impetus to publish quality manu-
scripts in a timely manner is strong. In addition, 
peer-reviewed studies supporting pharmaceutical 
companies’ products provide targeted advertising 
for these companies. Professional medical writ-
ers provide expertise in the presentation of sci-
entific data for researchers from both academia 
and corporations; however, when the participa-
tion of medical writers is obscured or the source 
of funding for these writers is not evident, editors, 
reviewers, and, most importantly, readers are 
unable to judge the potential biases or to evalu-
ate the quality of the data presented in the work.
The problem is not the use of medical writers 
per se, but the use of unacknowledged medical 
writers or the use of medical writers to prepare 
articles that list authors who have not contributed 
to the intellectual process of the article. In an edi-
torial piece in the Annals of Internal Medicine, 
Laine and Mulrow (2005) defined “ghostwriting” 
as a failure to acknowledge the individuals who 
wrote the paper and “guest authoring” as inclu-
sion of names of “individuals who did not con-
tribute substantially to the paper” on the byline. 
Typically, these guest authors are utilized to lend 
credibility to an article that has been funded by a 
pharmaceutical company to promote its products 
either directly or indirectly. In either case, the 
source of funding for the medical writing services 
may be concealed. Importantly, neither of these 
practices has a place in biomedical journals.
Although most of the instances of ghost author-
ship that have received media attention have 
related to clinical trials sponsored by pharma-
ceutical companies (for example, Fugh-Berman, 
2005; Mathews, 2005; Ngai et al., 2005), the 
topic is of importance and interest to the readers 
and authors of articles published in the Journal 
of Investigative Dermatology. First, the editors 
have expressed interest in receiving more high-
quality reports of clinical trials for consideration 
by the Journal (Williams and Goldsmith, 2006). 
Receiving more clinical trials, presumably with 
pharmaceutical support, increases the possibility 
of participation by a medical writer (Ngai et al., 
2005; Korieth, 2004). Second, and more impor-
tant, adhering to high ethics of authorship is 
essential for all submissions regardless of clinical 
nature or sponsor.
The International Committee of Medical 
Journal Editors’ (ICMJE’s) “Uniform 
Requirements for Manuscripts Submitted to 
Biomedical Journals” (2006), to which this jour-
nal adheres, has clear standards for authorship: 
“1) substantial contributions to conception and 
design, or acquisition of data, or analysis and 
interpretation of data; 2) drafting the article or 
revising it critically for important intellectual 
content; and 3) final approval of the version to 
be published. Authors should meet conditions 1, 
2, and 3.” Furthermore, “all persons designated 
as authors should qualify for authorship, and all 
those who qualify should be listed.” And “each 
author should have participated sufficiently in 
the work to take public responsibility for appro-
priate portions of the content.” Using these 
widely accepted criteria, most medical writers 
would not qualify for full authorship; however, 
the ICMJE asserts that “All contributors who do 
not meet the criteria for authorship should be 
listed in an acknowledgments section… Editors 
should ask authors to disclose whether they 
had writing assistance and to identify the entity 
that paid for this assistance.” When these clear 
guidelines are followed, the role of any medical 
writing assistance in the preparation of a study 
should be transparent.
But it is not just medical journal editors who 
have taken a stand on the role of medical writ-
ers in peer-reviewed research articles; the pro-
fessional societies for medical writers have 
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participated in the debate and offered guidelines in accord 
with the above standards. The American Medical Writers 
Association (AMWA) has published the following position 
statement on ghostwriting: “Biomedical communicators who 
contribute substantially to the writing or editing of a manu-
script should be acknowledged with their permission and 
with disclosure of any pertinent professional or financial rela-
tionships” (Hamilton and Royer, 2003).
Elizabeth Wager of the European Medical Writers 
Association (EMWA) has been particularly active in the dis-
cussion of the ethical role of medical writers. In a publica-
tion entitled “Good publication practice for pharmaceutical 
companies,” which is now widely cited for guiding pharma-
ceutical companies in the ethical role of professional medi-
cal writers, Wager and colleagues (2003) sought to “increase 
the transparency of the processes involved in the publication 
of industry-sponsored trials and to establish standards for 
these.” Specifically regarding the role of professional medi-
cal writers, Wager and colleagues’ guidelines call for “the 
contribution of the medical writer [to] be acknowledged,” 
while byline authors are responsible for determining the 
content, consulting with the medical writer before a draft 
is begun, commenting on the draft, and approving the final 
version. The Pharmaceutical Research and Manufacturers 
of America’s “Principles on Conduct of Clinical Trials and 
Communication of Clinical Trial Results” (2002) also states 
that contributions of company staff “should be recognized 
appropriately in resulting publications — either as a named 
author, a contributor, or in acknowledgments depending on 
their level of contribution.”
In a recent commentary, Jacobs and Wager explained that 
“involving medical writers and the appropriate role of spon-
sors are separate but sometimes overlap” (Jacobs and Wager, 
2005). The EMWA position statement on the role of medical 
writers in developing peer-reviewed publications emphasizes 
the "legitimate role” of medical writers “in assisting named 
authors in developing manuscripts for peer-reviewed jour-
nals” and that “such contributions and relevant information 
about funding should be openly acknowledged” (appen-
dix to Jacobs and Wager, 2005). In response to the EMWA 
guidelines, Daskalopoulou and Mikhailidis (2005) proposed 
a set of guiding principles for the interaction between pro-
fessional writers and authors. Their GATE principles refer to 
guarantee (Are the authors guarantors of the work?), advice 
(Did the authors advise the writer?), transparency (Is the writer 
acknowledged?), and expertise (Did the writer have sufficient 
expertise to draft the article?). These points serve to guide the 
ethical conduct of writers and authors in the generation of 
publications for submission to peer-reviewed journals.
One survey showed that less experienced authors with less 
confidence in their writing and English skills may be more 
interested in employing a medical writer than more senior 
researchers (Phillips et al., 2001). Senior authors with excel-
lent written-English skills, however, may also be inclined 
to employ a medical writer in order to decrease the time 
from data collection to publication (Wager et al., 2003). As 
a result, the market for medical writing appears to be grow-
ing steadily by about 15% each year (Korieth, 2004). While 
the reasons for working with a medical writer may be varied, 
working with medical writers can, in fact, be in compliance 
with accepted standards for writing articles and publishing in 
peer-reviewed biomedical journals (Laine and Mulrow, 2005; 
Woolley, 2006).
Clearly, transparency is the key to a harmonious relation-
ship between medical writers and the biomedical peer-
reviewed journals. In addition, journals can promote this 
relationship by adamantly opposing ghostwriters, accept-
ing and acknowledging the ethical use of professional medi-
cal writers, and requiring a contribution list to establish the 
role of all authors. Furthermore, more and more journals 
require signed conflict-of-interest statements for every pub-
lished article. The journals must take every reasonable step to 
ensure the dissemination of ethical science practices, but the 
accountability for the data and interpretation falls squarely on 
the shoulders of the contributing authors.
Moreover, readers of peer-reviewed articles must be 
assured that the authors, and not the medical writers, control 
the interpretation and the presentation of the data (Woolley, 
2006). The role of the medical writers, therefore, is to produce 
scientifically sound and accurate publications that are pub-
lished more quickly as a result, in part, of the writing skill of 
the professionals. In addition, disclosing the funding of the 
medical writers allows the readers to determine any potential, 
although not inevitable, bias in the publication.
The consensus among all of these groups is clear, and the 
expectation of the Journal of Investigative Dermatology is that 
the corresponding authors will guarantee that: 
(1)  Authors in the byline of submitted manuscripts meet 
ICMJE standards.
(2)  The contributions of medical writers not meeting the 
ICMJE standards are stated in the acknowledgments.
(3)  The funding for such writers, either through employ-
ment or through other sources, is stated in the acknow-
ledgments.
(4)  Authors are willing to take public responsibility for the 
scientific merit of the published work.
The World Association of Medical Editors provides perhaps 
the most concise explanation of the Journal of Investigative 
Dermatology editors’ desire, not only for authorship and 
acknowledgments but for all matter presented in submit-
ted manuscripts: “…present an honest account of what took 
place” (2007). If all parties — authors, pharmaceutical com-
panies, and medical writers — meet the professional stan-
dards expected of them, there will be no question of ethics.
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